PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseautoimmune disease (AID)immune checkpoint inhibitors (ICI)autoimmune liver diseases (AILD)immune related adverse effects (irAEs)PD-1/PD-L1 immune ...
为了模拟PD-L1-PD-1的自然结合,Immunocore设计了双特异性PD-1激动剂(*ImmTAAI®分子),特异性地结合靶细胞,并同时激活自身反应性T细胞上的PD-1。 *ImmTAAI® (Immune Modulating Monoclonal TCRs Against Autoimmune Disease)将重组PD-L1或抗PD-1激动剂抗...
5. Qiao Y, Qiu Y, Ding J, Luo N, Wang H, Ling X, Sun J, Wu Z, Wang Y, Liu Y, Guo F, Sun T, Shen W, Zhang M, Wu D, Chen B, Xu W, Wang X. Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity. Nat ...
[7] EDNER N M, CARLESSO G, RUSH J S, 等. Targeting co-stimulatory molecules in autoimmune disease[J]. Nature Reviews Drug Discovery, 2020, 19(12): 860-883. [8] MING J, CRONIN S J, PENNINGER J M. Targeting the RANKL/RANK/OPG ...
Targeted blockade of programmed-cell-death-protein-1 (PD-1)—an immune checkpoint factor expressed by activated T cells and B cells—is an efficacious therapy for potentiating immune activation against tumours. Here we show that an immunotoxin consisting of an anti-PD-1 single-chain variable ...
The PD-1 Inhibitor Drugs Market is expanding due to the rising prevalence of cancer and autoimmune diseases. PD-1 inhibitors, including pembrolizumab,...
1 In light of its success in cancer therapy, anti-PD-1/PD-L1 therapy has adequate precedent to be trialled in the treatment of severe chronic infectious diseases. Immune checkpoint inhibition in infectious disease therapy may be administered adjunctively to standard drug treatment − akin to ...
Nearly 30% of mice receiving combination therapy exhibited complete responses, whereas monotherapy only delayed tumor growth. This combination therapy pro- duced a side effect, however, as it led to progressive alopecia, an autoimmune disorder resulting in hair loss.77 In an attempt to restrict PD...
PD-1 contains the immunoreceptor tyrosine-based inhibitory motif (ITIM) and plays a key role in peripheral tolerance and autoimmune disease. PD-1 is expressed predominantly on activated T and B lymphocytes. Two novel members of the B7 family have been identified as the PD-1 ligands, PD-L1 (...
Additionally, this study examines the function of PD-1/PD-L1 as a suppressor of the immune response in the CRC microenvironment, as well as the potential advantages of administering inflammatory agents for CRC therapy. Finally, this study analyzes the outcomes of clinical trials to delve into ...